Stock Markets June 11, 2026 08:04 AM

Nvidia and Abridge to Build Clinical Conversation AI Using Nemotron Open Models

Partnership targets AI tuned for clinical dialogues, limited to Abridge's note-taking platform; Nvidia holds an equity stake

By Jordan Park
Share
Twitter Reddit Facebook LinkedIn
NVDA

Nvidia has entered a collaboration with Abridge to develop an AI model tailored to clinical conversations. The model will be trained on Nvidia's Nemotron suite of open models and will operate solely within Abridge's physician-focused note-taking platform, supporting documentation and clinical decision tasks. Nvidia also holds an investment stake in Abridge.

Nvidia and Abridge to Build Clinical Conversation AI Using Nemotron Open Models
NVDA
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Nvidia will partner with Abridge to develop an AI model focused on clinical conversations, to be used only within Abridge’s platform - impacts healthcare IT and clinical workflow sectors.
  • The model will be trained on Nvidia’s Nemotron suite of open models; open models are typically downloadable and adaptable at no cost but are not equivalent to open-source models with full access to training data and code - relevant to AI infrastructure and software development markets.
  • Stated intended uses include clinical decision support and documentation, aligning the project with digital health, electronic health record integration, and clinician productivity tools.

Nvidia announced on Thursday that it will work with Abridge to create an artificial intelligence model aimed specifically at healthcare conversations. Abridge, which produces an AI-driven note-taking application for physicians, will host the model within its own platform, the companies said.

The intended model will concentrate on clinical dialogues occurring between clinicians and patients or among care teams. According to Nvidia, the model's functionality is directed at supporting clinical decision support and documentation workflows, rather than broad consumer or third-party deployment. Nvidia also disclosed that it holds an investment stake in Abridge.

Model training and openness

Kimberly Powell, Nvidia's vice president of healthcare, said the company will base the training on its Nemotron suite of open models. Powell described open models as those typically available for users to download and adapt at no cost, while noting they are distinct from open-source models that provide full access to both training data and code.

"There’s an opportunity now to take these models and adapt them with this clinical intelligence at a much earlier stage of model development," Powell said.

Use limitations and stated aims

The partners emphasized that the AI will be used exclusively within Abridge’s platform. The stated aims include assisting with clinical decision support and easing documentation burdens for clinicians by leveraging a model tuned to the language and context of clinical conversations.

Sector interest

The announcement comes as a number of technology companies and AI research labs increase investment activity in healthcare-focused artificial intelligence. The collaboration is positioned at the intersection of health technology, clinical documentation, and AI model development, reflecting interest from both vendors of clinical workflow tools and AI infrastructure providers.


Summary

Nvidia and Abridge will build a healthcare AI model centered on clinical conversations, trained using Nvidia’s Nemotron open models, to operate solely within Abridge’s clinician-facing note-taking platform. The model is intended to support documentation and clinical decision tasks, and Nvidia holds an investment stake in Abridge.

Risks

  • The model is constrained to use within Abridge’s platform, which limits adoption to that user base and affects the commercial reach in digital health and health IT markets.
  • Open models are different from open-source models in that they do not necessarily provide full access to training data and code; this distinction could influence transparency and reproducibility concerns within healthcare AI development.
  • Details on training data and deployment safeguards were not provided in the announcement, leaving uncertainties around clinical validation and regulatory considerations for health technology and clinical decision support applications.

More from Stock Markets

Jefferies Lifts General Dynamics to Buy, Citing Submarine Backlog and Shipyard Productivity Jun 11, 2026 Microchip's Nantes Plant Adds Class Y QML Certification, Shares Tick Up Jun 11, 2026 Insider Moves: Major Purchases and Dispositions Reported for June 10, 2026 Jun 11, 2026 UBS Highlights Five European Construction Stocks Drawing Investor Focus Jun 11, 2026 Eaton to Spin Off Mobility Business in Reverse Morris Trust Deal with Dana; Shares Rally Premarket Jun 11, 2026